Target Research Field

• Cardiovascular System
• Central Nervous System
• Immuno-Inflammatory System

Compound in Pipeline

Feb. 2010

	Development Code	Generic Name	Indication / Class	Region (Alliance)	Stage
(1)	SUN Y7017	Memantine hydrochloride	Dementia of Alzheimer type / NMDA receptor antagonist	Japan	NDA
(2)	SUN11031	(Trivial Name) Human ghrelin	Cachexia	US/EU	PII
			Anorexia Nervosa	Japan	PIII
(3)	SUN13834	-	Atopic Dermatitis	US	PII
(4)	SUN N4057	-	Serotonin (5-HT) 1A receptor agonist	US/EU	PII

Pipeline in Development (1)
SUN Y7017

Development Code	Generic Name	Indication / Class	Route of Administration
SUN Y7017	Memantine hydrochloride	Dementia of Alzheimer type / NMDA receptor antagonist	Oral

Origin	Region	Alliance	Stage
Merz	Japan	Daiichi Sankyo (Sales & Promotion)	Application

Characteristic
Memantine, categorized as an antagonist of the NMDA receptor which is one of the glutamate receptor subtypes in the central nervous system in mammals, possesses therapeutic action for dementia of Alzheimer type. The drug is expected to demonstrate effectivity in slowing down the progression of the disease by its neuroprotective action, which is distinct from cholinesterase inhibitors.

Pipeline in Development (2)
SUN11031

Development Code	Generic Name	Indication / Class	Route of Administration
SUN11031	(Trivial Name) Human ghrelin	Cachexia (US/EU) Anorexia Nervosa (Japan)	Injection

Origin	Region	Alliance	Stage
Asubio	US/EU	-	PII
	Japan		PIII

Characteristic
Ghrelin is an endogenous peptide known as one-and-only peripheral appetite stimulator among all hormones discovered the relationship with feeding behavior up to now. In addition to it, ghrelin is a potent stimulator of growth hormone release. Asubio has been conducting the research and development of ghrelin as a therapeutic agent for cachexia in various diseases and for anorexia nervosa.

Pipeline in Development (3)
SUN 13834

Development Code	Generic Name	Indication / Class	Route of Administration
SUN13834	-	Atopic Dermatitis/Chymase Inhibitor	Oral

Origin	Region	Alliance	Stage
Asubio	US	-	PII

Characteristic

SUN13834 is a chymase inhibitor currently under Phase II investigation for the treatment of atopic dermatitis (AD), commonly known as eczema. Chymase is a chymotrypsin-like serin protease exclusively stored in secretory granules of mast cells and is thought to participate in allergic inflammatory diseases. Preclinical models have suggested that inhibition of chymase with SUN13834 may reduce the inflammation and pruritus associated with atopic dermatitis.

Pipeline in Development (4)
SUN N4057

Development Code	Generic Name	Indication / Class	Route of Administration
SUN N4057	-	Serotonin (5-HT) 1A receptor agonist	Injection/Oral

Origin	Region	Alliance	Stage
Asubio	US/EU	-	PII

Characteristic
SUN N4057 is a neuroprotective agent that increases cerebral inhibitory neurotransmission via activation of serotonin (5-HT) 1A receptors. SUN N4057 can inhibit ischemic neuronal death and is expected to minimize infarction size during the acute stage and improve prognosis in acute stroke patients.